 |
|
Looking beyond the drug receptor for clues to drug effectiveness
August 26, 2008DURHAM, N.C. - Antipsychotic drugs that are widely used to treat schizophrenia and other problems may not work as scientists have assumed, according to findings from Duke University Medical Center researchers that could lead to changes in how these drugs are developed and prescribed.
Scientists have known that all antipsychotic drugs target the D2 receptor inside cells. New tests developed at Duke reveal that the biochemical pathways linked to this receptor - the pathways along which the drugs deliver their therapeutic effects - may function differently than previously understood.
The Duke team developed specialized tests and studied two main pathways that stem from the receptor. The first is the G-protein-dependent signaling pathway, and the other is the beta arrestin pathway.
Most antipsychotic drugs in use today were developed to target the G-protein signaling that occurs at the receptor. Only recently, beta-arrestin, a protein known as an "off-switch" for G-protein receptors, has been shown to also play a role in directing other cellular activities.
The tests uncovered surprising results. "Our work showed that all nine antipsychotic drugs we examined uniformly and more potently block the beta-arrestin pathway downstream of the D2 dopamine receptor," said Bernard Masri, Ph.D., lead author and postdoctoral researcher in the Duke Department of Cell Biology.
The drugs, however, showed a variety of effects at the G-protein pathway. "Some activated it, some blocked the G side totally, some blocked it only 50 percent - the drugs had different profiles for the G-protein pathway," Masri said. "So with this new information, drug manufacturers would want to make sure new compounds for antipsychotic use block the beta-arrestin pathway."
There may be even more pathways not yet known to flow from the D2 receptor, he added, pointing up the difficulty of developing a drug with the greatest possible effectiveness and fewest side effects. To further complicate the situation, antipsychotic drugs also work on receptors other than the D2 receptor. The drugs are used mainly to treat schizophrenia, which affects about 1 percent of people in the United States.
G-protein coupled receptors have been the most common target of such therapeutic drugs. The findings about beta arrestin's dual role open possibilities for developing new drugs. The importance of this concept for G-protein coupled receptors, especially the dopamine receptor, was demonstrated at Duke by the acclaimed receptor pioneer Robert J. Lefkowitz, M.D., and Marc G. Caron, Ph.D., the senior author on the current study.
"This work with antipsychotic drugs represents an entirely new approach for studying drug effects and developing new ones," Masri said of the Duke team's research, published the week of Aug. 25-29 in the Proceedings of the National Academy of Sciences.
In this study, the scientists used a technique called bioluminescence resonance energy transfer (BRET) in cells in culture. "Using cells to monitor specific receptor signaling pathways could provide more selective medicines with fewer side effects," said co-author Ali Salahpour, Ph.D., also a postdoctoral researcher in cell biology. "This is where pharmaceutical research is headed."
BRET is a luminescence-based technique that monitors interactions between molecules. One assay in this study followed the variation of cyclic adenosine monophosphate to look at the G-protein dependent pathway, and the other measured the direct interaction of beta arrestin with the dopamine D2 receptor. The antipsychotics were tested with both assays to look at which pathway(s) they were activating or blocking, and with what strength and efficacy.
Marc Caron, Ph.D., James B. Duke Professor in the Department of Cell Biology and director of the research laboratory, said, "Using these assays as a means to develop antipsychotics should be a useful way to target precise responses and improve patient symptoms." Unwanted side-effects, such as spasms or movement problems that cause the whole body or parts of the body to move uncontrollably, are associated with some of the antipsychotic drugs studied.
"Not all drugs used for schizophrenia have the same degree of movement-related side effects," Caron said. "For some of the drugs, these side effects may stem from interactions on the G protein part of the pathways." Therefore, evaluating antipsychotic drugs early that act less or not at all on the G side, but are effective on the beta arrestin side, could provide improved efficacy with many fewer side effects.
The next project for the scientists is to study these drugs and the relevant pathways in both normal mice and mice with traits of psychosis.
Duke University Medical Center
Most antipsychotic drugs in use today were developed to target the G-protein signaling that occurs at the receptor. Only recently, beta-arrestin, a protein known as an "off-switch" for G-protein receptors, has been shown to also play a role in directing other cellular activities.
The tests uncovered surprising results. "Our work showed that all nine antipsychotic drugs we examined uniformly and more potently block the beta-arrestin pathway downstream of the D2 dopamine receptor," said Bernard Masri, Ph.D., lead author and postdoctoral researcher in the Duke Department of Cell Biology.
The drugs, however, showed a variety of effects at the G-protein pathway. "Some activated it, some blocked the G side totally, some blocked it only 50 percent - the drugs had different profiles for the G-protein pathway," Masri said. "So with this new information, drug manufacturers would want to make sure new compounds for antipsychotic use block the beta-arrestin pathway."
There may be even more pathways not yet known to flow from the D2 receptor, he added, pointing up the difficulty of developing a drug with the greatest possible effectiveness and fewest side effects. To further complicate the situation, antipsychotic drugs also work on receptors other than the D2 receptor. The drugs are used mainly to treat schizophrenia, which affects about 1 percent of people in the United States.
G-protein coupled receptors have been the most common target of such therapeutic drugs. The findings about beta arrestin's dual role open possibilities for developing new drugs. The importance of this concept for G-protein coupled receptors, especially the dopamine receptor, was demonstrated at Duke by the acclaimed receptor pioneer Robert J. Lefkowitz, M.D., and Marc G. Caron, Ph.D., the senior author on the current study.
"This work with antipsychotic drugs represents an entirely new approach for studying drug effects and developing new ones," Masri said of the Duke team's research, published the week of Aug. 25-29 in the Proceedings of the National Academy of Sciences.
In this study, the scientists used a technique called bioluminescence resonance energy transfer (BRET) in cells in culture. "Using cells to monitor specific receptor signaling pathways could provide more selective medicines with fewer side effects," said co-author Ali Salahpour, Ph.D., also a postdoctoral researcher in cell biology. "This is where pharmaceutical research is headed."
BRET is a luminescence-based technique that monitors interactions between molecules. One assay in this study followed the variation of cyclic adenosine monophosphate to look at the G-protein dependent pathway, and the other measured the direct interaction of beta arrestin with the dopamine D2 receptor. The antipsychotics were tested with both assays to look at which pathway(s) they were activating or blocking, and with what strength and efficacy.
Marc Caron, Ph.D., James B. Duke Professor in the Department of Cell Biology and director of the research laboratory, said, "Using these assays as a means to develop antipsychotics should be a useful way to target precise responses and improve patient symptoms." Unwanted side-effects, such as spasms or movement problems that cause the whole body or parts of the body to move uncontrollably, are associated with some of the antipsychotic drugs studied.
"Not all drugs used for schizophrenia have the same degree of movement-related side effects," Caron said. "For some of the drugs, these side effects may stem from interactions on the G protein part of the pathways." Therefore, evaluating antipsychotic drugs early that act less or not at all on the G side, but are effective on the beta arrestin side, could provide improved efficacy with many fewer side effects.
The next project for the scientists is to study these drugs and the relevant pathways in both normal mice and mice with traits of psychosis.
Duke University Medical Center
Antipsychotic Drug Current Events and Antipsychotic Drug News RSSPitt research identifies new target in brain for treating schizophrenia
Research from the University of Pittsburgh could expand the options for controlling schizophrenia by identifying a brain region that responds to more than one type of antipsychotic drug.
Risks and benefits of antipsychotics in children and adolescents
Many of the psychiatric disorders observed in adults have their onset in childhood or adolescence. In fact some studies show that at least 20% of children and adolescents will fulfil a diagnostic criterion for a mental disorder before reaching adulthood.
Short-term use of antipsychotics in older adults with dementia linked to serious adverse events
Older adults with dementia who receive short-term courses of antipsychotic medications are more likely to be hospitalized or die than those who do not take the drugs, according to a report in the May 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Hopkins researchers discover new link to schizophrenia
Neuroscientists at Johns Hopkins have discovered that mice lacking an enzyme that contributes to Alzheimer disease exhibit a number of schizophrenia-like behaviors.
Treatment With An Antipsychotic Drug Found To Cause Changes In Metabolism Earlier Than Expected
Schizophrenia is a complex type of psychotic mental illness characterized by thoughts that are uncoupled from reality.
Common treatment for methamphetamine overdose may damage brain cells
A common antipsychotic drug used in emergency rooms to treat methamphetamine overdose damages nerve cells in an area of the brain known to regulate movement, a new study shows.
Antipsychotic drug may block addiction, UIC researchers find
Researchers at the University of Illinois at Chicago have discovered that a long-approved oral antipsychotic drug can stop the addictive properties of opioid painkillers in mice.
Atypical antipsychotic drugs for dementia may be associated with small increased risk of death
Patients with dementia who took atypical antipsychotic drugs had a slightly increased risk of death compared to patients who took placebo, according to a meta-analysis published in the October 19 issue of JAMA.
Top Psychiatry Researchers Honoured with International Career Development Award
American Psychiatric Association and AstraZeneca Reward '2004 Young Minds in Psychiatry' Winners
New-generation Antipsychotic Drugs May Have Similar Neurological Side-effects To Conventional Drugs (p 1581)
Authors of a systematic review of antipsychotic drugs in this week's issue of THE LANCET highlight how the better side-effect profile of new-generation drugs may not be as substantial as previously thought when compared with conventional antipsychotics. New-generation drugs are generally more efficacious, although older-generation antipsychotics are still a cost-effective option for treating disorders such as schizophrenia in resource-poor settings. The main advantage of new-generation antipsychotic drugs is a reduced risk of side-effects compared with conventional drugs. However, there is debate that the reduced side-effects of the new-generation class of drugs is based on trials that cou
More Antipsychotic Drug Current Events and Antipsychotic Drug News Articles
| Antipsychotic Drugs, Pharmacodynamics and Pharmacokinetics: Proceedings of the International Symposium Held in Wenner-Gren Center, Stockholm, Septembe ... Library of Science, Technology, Engin) | |
 | Essential Psychopharmacology of Antipsychotics and Mood Stabilizers (Essential Psychopharmacology Series) by Stephen M. Stahl Drawn from the best-selling second edition of Essential Psychopharmacology, Steve Stahl has revised and updated the chapters covering antipsychotics and mood stabilizers in this separate volume. This new book covers the many dimensions of psychosis, particularly as associated with schizophrenia, and examines the role of dopamine in psychosis along with the various theories about the causes,... |
| Novel Antipsychotic Drugs by Herbert Y., ed Meltzer | |
| Gale Encyclopedia of Medicine: Antipsychotic drugs by Samuel D. Uretsky PharmD The article is excerpted from Gale Encyclopedia of Medicine. Consult the second edition of this authoritative, comprehensive, in-depth medical guide for information on more than 1,700 medical topics in language accessible to adult laypersons. Presented in a single alphabetical sequence, articles range in length from one or two paragraphs for minor topics, to several pages or more for major... | |
| Gale Encyclopedia of Medicine: Antipsychotic drugs, atypical by Samuel D. Uretsky PharmD The article is excerpted from Gale Encyclopedia of Medicine. Consult the second edition of this authoritative, comprehensive, in-depth medical guide for information on more than 1,700 medical topics in language accessible to adult laypersons. Presented in a single alphabetical sequence, articles range in length from one or two paragraphs for minor topics, to several pages or more for major... | |
 | A Guide to the Extrapyramidal Side Effects of Antipsychotic Drugs by D. G. Cunningham Owens Antipsychotic drugs have revolutionized the management of major psychiatric disorders and the outcomes of those who suffer from them. However, they often contribute to a range of adverse effects, among the most frequent and distressing of which are those resulting in disturbance of voluntary motor function. Extrapyramidal side effects--or EPS--are still poorly recognized and frequently... |
| Forced competence: a defendant's right to reject involuntarily administered antipsychotic drug treatment.: An article from: Jones Law Review by April Logan This digital document is an article from Jones Law Review, published by Thomson Gale on January 1, 2004. The length of the article is 6726 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Forced... | |
| Novel Antipsychotic Drugs | |
 | Antipsychotic Drugs and Their Side-Effects (Neuroscience Perspectives) In line with other volumes in the Neuroscience Perspectives Series, this volume covers the background, pharmacology, molecular biology, and biochemistry of antipsychotic drugs, together with an overview assessment of the therapeutic considerations. Over the past 40 years, the effectiveness of conventional neuroleptic agents for psychotic illness has been offset by a wide range of adverse... |
| Antipsychotic drugs: An entry from Thomson Gale's Gale Encyclopedia of Nursing and Allied Health by Samuel D., PharmD Uretsky The “Gale Encyclopedia of Nursing and Allied Health” is an alphabetically arranged five-volume set of more than 850 entries written for students and professionals in the field. Topics include body systems and functions, conditions and common diseases, issues and theories, techniques and practices, and devices and equipment. The Encyclopedia covers all major health professions, including... |
| © 2008 BrightSurf.com |